www.CHESTERCMS.org Future Research and Important Remaining Questions As the SGLT2i is further explored and characterized, there a few questions of immediate interest: 1. What important differences exist among the individual SGLT2i derivatives? Figure 17: SGLT2i treatments are recommended to patients to prevent and treat heart failure 2. Will the benefits of the SGLT2i remain as a long-term solution for patients? Indications for SGLT2 inhibitors: 3. What other diabetic and cardiovascular medications can the SGLT2i be combined with to offer beneficial outcomes? ·To reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction ·To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established CV disease or multiple CV risk factors ·As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus This article was written in collaboration between Mian A. Jan, M.D., Chairman, Department of Medicine Penn Medicine Chester County Hospital, and Ankit Raina, an intern at West Chester Cardiology. Accelerate Your Business Owner-Occupied Commercial Mor tgages No prepayment penalt y Flexible payment terms Get star ted by contacting Chief Relationship Of f icer Marc Ernest 484-259-1852 marce@fmfcu.org Locally Headquar tered SPRING 2021 | CHESTER COUNT Y Medicine 13http://www.chestercms.org